PAMINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PAMINE (PAMINE).
Antimuscarinic; competitively blocks acetylcholine at muscarinic receptors, reducing smooth muscle spasm and secretions.
| Metabolism | Hepatic via CYP450 enzymes (minimal data); primarily excreted unchanged in urine. |
| Excretion | Primarily renal (70-80% unchanged), with 20-30% fecal via biliary elimination. |
| Half-life | 1.5-2 hours, necessitating dosing every 4-6 hours for sustained therapeutic effect. |
| Protein binding | 25-30%, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 2-3 L/kg, indicating extensive tissue distribution beyond plasma volume. |
| Bioavailability | Oral: 10-20% due to extensive first-pass metabolism; Intravenous and intramuscular: 100%. |
| Onset of Action | Oral: 1 hour; Intravenous: 1-2 minutes; Intramuscular: 10-15 minutes. |
| Duration of Action | 4-6 hours, with shorter duration in patients with hypermotility or accelerated GI transit. |
2.5 mg orally or subcutaneously 30-60 minutes before meals and at bedtime; maximum 10 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific GFR-based guidelines; use with caution in severe renal impairment (CrCl <30 mL/min) due to reduced clearance. |
| Liver impairment | No adjustment required for Child-Pugh A or B; for Child-Pugh C, consider dose reduction by 50% due to increased bioavailability. |
| Pediatric use | 0.25-0.5 mg/kg orally 4-6 times daily; not recommended in infants <3 months. |
| Geriatric use | Initiate at 1.25 mg orally 2-3 times daily due to increased anticholinergic sensitivity and risk of confusion, falls, and urinary retention. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PAMINE (PAMINE).
| Breastfeeding | Methscopolamine is excreted into breast milk in small amounts; M/P ratio not established. Anticholinergic effects in the infant (e.g., tachycardia, constipation, irritability) are possible, but unlikely at maternal therapeutic doses. Monitor infant for signs of anticholinergic toxicity. Caution recommended; consider alternative therapy if infant is sensitive. |
| Teratogenic Risk | Pamline (methscopolamine) is an anticholinergic agent. Animal studies have not demonstrated teratogenicity; however, no adequate well-controlled studies in pregnant women exist. First trimester: No definitive evidence of malformations, but anticholinergics may be associated with minor anomalies if used chronically. Second and third trimesters: Risk of neonatal anticholinergic effects (e.g., meconium ileus, respiratory depression) if used near term. Fetal risk cannot be excluded. Use only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Glaucoma (narrow-angle)","Obstructive uropathy (e.g., prostatic hypertrophy)","Obstructive gastrointestinal tract disease (e.g., pyloroduodenal stenosis)","Myasthenia gravis","Unstable cardiovascular status in acute hemorrhage","Severe ulcerative colitis","Toxic megacolon"]
| Precautions | ["Heat prostration can occur in high temperature environments due to decreased sweating","May cause drowsiness or blurred vision; avoid hazardous activities","Use with caution in patients with glaucoma, prostatic hypertrophy, or gastrointestinal obstruction","Elderly patients may be more sensitive to anticholinergic effects","May exacerbate tachyarrhythmias"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, urinary retention, and signs of anticholinergic toxicity (e.g., blurred vision, dry mouth, constipation). Fetal monitoring: assess fetal heart rate and movement; consider ultrasound for growth if prolonged use. In neonates, monitor for anticholinergic effects: constipation, temperature instability, respiratory depression. |
| Fertility Effects | Anticholinergic effects may theoretically alter cervical mucus or impair implantation, but no human data specific to methscopolamine. No significant impact on spermatogenesis or oogenesis reported. No fertility studies in humans; animal studies show no adverse effects on fertility. |